[
  {
    "ts": null,
    "headline": "BDX Unveils Portable PureWick System for On-the-Go Incontinence Care",
    "summary": "BD expands its PureWick line with a portable system built for discreet, mobile incontinence care, aiming to deepen its home-care reach.",
    "url": "https://finnhub.io/api/news?id=59f0beb1c0f10f1ebbd896991a070b0487928cb1a9e36f1dcb5a48c94011f63c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763060400,
      "headline": "BDX Unveils Portable PureWick System for On-the-Go Incontinence Care",
      "id": 137473265,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "SOLV",
      "source": "Yahoo",
      "summary": "BD expands its PureWick line with a portable system built for discreet, mobile incontinence care, aiming to deepen its home-care reach.",
      "url": "https://finnhub.io/api/news?id=59f0beb1c0f10f1ebbd896991a070b0487928cb1a9e36f1dcb5a48c94011f63c"
    }
  },
  {
    "ts": null,
    "headline": "STXS Secures FDA Approval for GenesisX to Broaden Surgical Robotics",
    "summary": "Stereotaxis wins FDA clearance for GenesisX, a streamlined robotic system aimed at boosting hospital adoption and accelerating growth.",
    "url": "https://finnhub.io/api/news?id=13ca248395859558f9fe9a0396c982c8989644b154f79eb2c16133bad3040dec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763060220,
      "headline": "STXS Secures FDA Approval for GenesisX to Broaden Surgical Robotics",
      "id": 137473329,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "SOLV",
      "source": "Yahoo",
      "summary": "Stereotaxis wins FDA clearance for GenesisX, a streamlined robotic system aimed at boosting hospital adoption and accelerating growth.",
      "url": "https://finnhub.io/api/news?id=13ca248395859558f9fe9a0396c982c8989644b154f79eb2c16133bad3040dec"
    }
  },
  {
    "ts": null,
    "headline": "Solventum Stock: Analyst Estimates & Ratings",
    "summary": "Solventum has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.",
    "url": "https://finnhub.io/api/news?id=246e87ab6337f9981e4cbf02954ae15b3a545b7819b8542270569149e1bd4c63",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763040200,
      "headline": "Solventum Stock: Analyst Estimates & Ratings",
      "id": 137469431,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "SOLV",
      "source": "Yahoo",
      "summary": "Solventum has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.",
      "url": "https://finnhub.io/api/news?id=246e87ab6337f9981e4cbf02954ae15b3a545b7819b8542270569149e1bd4c63"
    }
  },
  {
    "ts": null,
    "headline": "5 Must-Read Analyst Questions From Solventum’s Q3 Earnings Call",
    "summary": "Solventum’s third quarter results met Wall Street’s revenue expectations and exceeded consensus for non-GAAP earnings, with organic growth led by volume improvements across key segments. Management attributed the performance to execution on its three-phase transformation plan, including commercial restructuring, supply chain enhancements, and a sharpened product innovation process. CEO Bryan Hanson highlighted that “commercial and new innovation enhancements are delivering faster and more materi",
    "url": "https://finnhub.io/api/news?id=34b32fb146bf7038cb848748b66d0a6894793d1195e7edca490b9198553bbbe4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763011954,
      "headline": "5 Must-Read Analyst Questions From Solventum’s Q3 Earnings Call",
      "id": 137468550,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "SOLV",
      "source": "Yahoo",
      "summary": "Solventum’s third quarter results met Wall Street’s revenue expectations and exceeded consensus for non-GAAP earnings, with organic growth led by volume improvements across key segments. Management attributed the performance to execution on its three-phase transformation plan, including commercial restructuring, supply chain enhancements, and a sharpened product innovation process. CEO Bryan Hanson highlighted that “commercial and new innovation enhancements are delivering faster and more materi",
      "url": "https://finnhub.io/api/news?id=34b32fb146bf7038cb848748b66d0a6894793d1195e7edca490b9198553bbbe4"
    }
  }
]